Glucagon-like peptide-1 (GLP-1) inhibitors may reduce progression of renal disease in type 2 diabetes [107,108], but these drugs have serious gastrointestinal effects and might increase the risk of pancreatitis and/or tumors [109]. Here, GCG is linked to type 2 diabetes mellitus.